Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions.
- Share Price (Ordinary Shares): 1463 pence
- Share Price (ADS): $47.45
- Transaction Date: October 9, 2012
- Dividend Payment Date: October 4, 2012
Material Changes
The filing details increases in notional interests in Ordinary Shares and American Depositary Shares (ADSs) for specific directors and connected persons following the notional re-investment of dividends. No material changes to the company's financial position or operations are reported in this document.
- Dr M M Slaoui: Increase of 18.825 ADSs (Connected Person: Dr K Slaoui).
- Mr P C Thomson: Increase of 49.326 Ordinary Shares (Connected Person: Mrs K Thomson).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document notes that notional dividends accrued will be paid out in proportion to the percentage of the participant's Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Investor Verification Checklist
- Verify the vesting schedule and conditions for the GlaxoSmithKline Performance Share Plan.
- Confirm the total number of shares held by Dr M M Slaoui and Mr P C Thomson post-transaction.
- Review the full dividend declaration details for the October 4, 2012 payment.
- Check for any subsequent filings regarding the actual payout of notional dividends upon vesting.